|
Intellectual Disability
|
0.410 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder.
|
29069077 |
2017 |
|
Intellectual Disability
|
0.410 |
Biomarker
|
group |
BEFREE |
Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder.
|
29069077 |
2017 |
|
Intellectual Disability
|
0.410 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability.
|
22726846 |
2012 |
|
Intellectual Disability
|
0.410 |
Biomarker
|
group |
HPO |
|
|
|
|
KLEEFSTRA SYNDROME 2
|
0.400 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Histone Lysine Methylases and Demethylases in the Landscape of Human Developmental Disorders.
|
29276005 |
2018 |
|
KLEEFSTRA SYNDROME 2
|
0.400 |
GeneticVariation
|
disease |
CLINVAR |
Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder.
|
29069077 |
2017 |
|
KLEEFSTRA SYNDROME 2
|
0.400 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability.
|
22726846 |
2012 |
|
KLEEFSTRA SYNDROME 2
|
0.400 |
GeneticVariation
|
disease |
CLINVAR |
Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability.
|
22726846 |
2012 |
|
KLEEFSTRA SYNDROME 2
|
0.400 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Leukemia, Myelocytic, Acute
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
|
29384595 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
Biomarker
|
disease |
BEFREE |
To evaluate the prognostic impact of gene expression levels (ELs) of two tumor suppressor genes, sprouty 4 (SPRY4, located on 5q) and lysine methyltransferase 2C (KMT2C, located on 7q) in correlation with clinical characteristics and genetic abnormalities assessed at initial diagnosis in acute myeloid leukemia (AML).
|
28940816 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Aberrant DNA methylation of acute myeloid leukemia and colorectal cancer in a Chinese pedigree with a MLL3 germline mutation.
|
27405564 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
Biomarker
|
disease |
BEFREE |
Therefore, we propose that MLL3 loss in patients may contribute to the progression of MDS and AML by promoting myelopoiesis.
|
27610619 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
Biomarker
|
disease |
BEFREE |
In this issue of Cancer Cell, Chen and colleagues identify MLL3 as a novel haplo-insufficient tumor suppressor on 7q that, in combination with NF1 suppression and TP53 deficiency, mediates MDS and AML phenotypes in mouse and human systems.
|
24823633 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
Biomarker
|
disease |
BEFREE |
Using RNAi and CRISPR/Cas9 approaches, we show that an ∼50% reduction in gene dosage of the mixed lineage leukemia 3 (MLL3) gene, located on 7q36.1, cooperates with other events occurring in -7/del(7q) AMLs to promote leukemogenesis.
|
24794707 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
Biomarker
|
disease |
CTD_human |
Interestingly, Mll3-suppressed leukemias, like human -7/del(7q) AMLs, are refractory to conventional chemotherapy but sensitive to the BET inhibitor JQ1.
|
24794707 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
Biomarker
|
disease |
BEFREE |
Of our candidate genes, we found that MLL3 was a compound heterozygote in every infant who developed AML and 50% of infants who developed ALL.
|
24301523 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
In one case of AML with del(11)(q23), deletion of the MLL 3' region and the region telomeric to the MLL gene was seen.
|
15350305 |
2004 |
|
Malignant neoplasm of stomach
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Mutations in chromatin remodeling genes (ARID1A, MLL3 and MLL) have been found in 47% of GCs.
|
24744582 |
2014 |
|
Malignant neoplasm of stomach
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to examine the expression of MLL3 in tissue samples of patients with gastric cancer and to analyze the relationship between MLL3 protein expression and clinical records.
|
25222251 |
2014 |
|
Malignant neoplasm of stomach
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to investigate the association of a missense mutation (S3660L) in the MLL3 gene with gastric cancer risk in a Chinese population.
|
24965397 |
2014 |
|
Malignant neoplasm of stomach
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
We also analyzed MLL3 expression in GC and CRC tissues using immunohistochemistry.
|
23259788 |
2013 |
|
Malignant neoplasm of stomach
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Our results for the first time provided new insight into susceptibility factors of MLL3 gene variants in carcinogenesis of gastric cancer of the Chinese Han population.
|
23991983 |
2013 |
|
Malignant neoplasm of stomach
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Frequent mutations in chromatin remodeling genes (ARID1A, MLL3 and MLL) also occurred in 47% of the gastric cancers.
|
22484628 |
2012 |
|
Malignant neoplasm of stomach
|
0.360 |
Biomarker
|
disease |
CTD_human |
Frequent mutations in chromatin remodeling genes (ARID1A, MLL3 and MLL) also occurred in 47% of the gastric cancers.
|
22484628 |
2012 |